Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

870 - Selective Wnt/β-catenin small-molecule inhibitor CWP232228 impairs tumor growth of colon cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Jin Young Kim


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


J.Y. Kim1, K.K. Lee1, E.H. Jung1, E. Ha2, M. Krishnan2, K. Chun3

Author affiliations

  • 1 Hemato-oncology, Dongsan Medical Center Kemyung University Hospital, 700-712 - Daegu/KR
  • 2 Biochemistry, School of Medicine, Keimyung University, 41931 - Daegu/KR
  • 3 Pharmacy, College of Pharmacy, Keimyung University, 41931 - Daegu/KR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 870


Aberrant activation of Wnt/β-catenin signaling is commonly found in colorectal cancers (CRCs) and is the prime event involved in the rapid proliferation of tumor cells in patients with advanced CRC. However, the limited effects of current therapeutics are unsatisfying, which highlights the importance of novel interventions in CRC chemo-treatment. We designed a highly potent small-molecule inhibitor CWP232228, which antagonizes binding of β-catenin to T cell factor in the nucleus. Thus, the present study aimed to explore the possibility of a selective small molecule β-catenin inhibitor, CWP232228, as a potential therapeutic drug in the treatment of CRCs.


We observed that CWP232228 at a concentration of as low as 1.0 μM induced significant cytotoxic effectsand apoptosis in HCT116. Immunoblot analysis showed that CWP232228 treatment increased the release of cytochrome C, which led to the activation of apical (caspase-9) and effector caspases (caspase-7 and -3) resulting in the increased cleavage of PARP.


In addition, we observed that CWP232228 caused cell cycle arrest via attenuating the expressions of cyclin D2, D3, and survivin. Thus, we validated decreased expressions of Wnt/β-catenin targeted cell cycle progression regulators, aurora kinase A, c-Myc, cyclin D1, and microphthalmia-associated transcription factor.


We confirmed that CWP232228 targets β-catenin via decreased promoter activities, nuclear expressions of β-catenin. Lastly, we found CWP232228 also inhibited growth of xenografted colon cancer cells in NOD-scid IL2Rgammanull mice. Collectively, results in the current study showed a possibility for CWP232228 as a potential therapeutic drug in CRCs.

Clinical trial identification

Editorial acknowledgement

This article is based on research supported by JW pharamaeutical.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.